altRx vs TMates: Affordable GLP-1 vs 24/7 Doctor Access
Comparing altRx vs TMates quickly: altRx positions itself as the lowest-cost compounded GLP-1 option with semaglutide starting at $89/month and tirzepatide at $149/month, while TMates offers a flat $199/month semaglutide program with 24/7 access to U.S.-based doctors. Early verdict: choose altRx if price and a minimal-commitment, 100% online start matter most; choose TMates if you want continuous physician availability and a flat-rate model across doses.
Key differences at a glance: price, clinician access, formulation, availability
This comparison focuses on the most distinctive supported differences between altRx and TMates: pricing structure, clinician access and oversight, which compounded medications are emphasized, state coverage and shipping, and membership or payment features. The evidence is taken directly from each provider’s materials.
Pricing structure and transparency
altRx advertises a limited offer with compounded semaglutide starting at $89/month and compounded tirzepatide at $149/month. The altRx materials also present multi-month plan reductions for semaglutide and tirzepatide, and emphasize “same price every month” and “no membership, insurance or hidden fees.” TMates positions itself as a flat $199/month program for semaglutide, “same price all doses,” with published multi-month tiers that show higher per-month amounts on shorter plans but a flat list price of $199/month stated on landing content.
Clinician access and medical oversight
altRx: 100% online medical visits with a licensed clinician, ongoing clinician-guided support from a care team, and a licensed provider who reviews the health evaluation and may conduct telehealth via live video or asynchronous review based on state telehealth laws. TMates: emphasizes 24/7 access to U.S.-based doctors and virtual check-in appointments, describing actual physician availability rather than messaging-only support.
Medication formulation and regulatory notes
Both providers supply compounded semaglutide; altRx explicitly markets compounded semaglutide and compounded tirzepatide and notes state-licensed 503A compounding pharmacies. TMates highlights clinically dosed compounded semaglutide formulated in U.S.-based facilities and notes compounded medication status. Both sources include the regulatory qualifier that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
| Criteria | altRx | TMates |
|---|---|---|
| Starting price | Semaglutide from $89/mo; Tirzepatide $149/mo | $199/month flat (semaglutide) |
| Price model | Limited offer, multi-month discounts, “same price every month” | Flat $199/mo at every dose; published multi-month tiers |
| Clinician access | 100% online medical visits; licensed provider review; care team support | 24/7 access to U.S.-based doctors; virtual check-ins |
| Medication type | Compounded semaglutide and compounded tirzepatide via 503A pharmacies | Clinically dosed compounded semaglutide formulated in U.S. facilities |
| Shipping and delivery | Free, discreet 2-day delivery; typical processing 4-5 business days | Free shipping; ships to most states subject to medical eligibility |
| State coverage | Membership available to residents of all 50 U.S. states; provider availability varies | Licensed coverage in all 50 states; availability based on medical eligibility |
How onboarding and ongoing care differ
altRx describes a 2-minute quiz to start, a licensed clinician review, and that if treatment is appropriate a prescription is sent to a licensed pharmacy for fulfillment with ongoing care team support. TMates emphasizes personalized, doctor-supervised dosing, virtual check-ins, and continuous physician access for questions about technique, side effects, and dose adjustments.
Who benefits from the medication choices each highlights
altRx highlights both compounded semaglutide and compounded tirzepatide as options and markets tirzepatide pricing explicitly. TMates primarily highlights compounded semaglutide and notes limited public detail on tirzepatide availability. If access to tirzepatide is a deciding factor, the provided altRx materials explicitly list tirzepatide pricing and options; TMates materials show strong emphasis on semaglutide.
Safety, regulatory qualifiers, and cancellations
Both providers are clear in their materials that supplied medications are compounded and therefore not FDA-approved finished products. altRx and TMates both state cancel anytime policies in their respective content. altRx lists state-licensed 503A compounding pharmacies and specifies that prescriptions are filled by independently owned and operated compounding pharmacies in its network; TMates states medications are formulated in U.S.-based facilities.
Final comparison and recommendation
In a direct altRx vs TMates comparison, the biggest tradeoffs are price versus continuous physician access and a flat-rate dose policy. altRx is built around an affordability claim with semaglutide starting at $89/month and tirzepatide at $149/month plus 100% online visits and free 2-day delivery. TMates charges a higher flat rate of $199/month for semaglutide but highlights 24/7 U.S.-based doctor access and a consistent per-dose price model.
Choose altRx if you prioritize lower starting price, 100% online visits, compound GLP-1 options including tirzepatide at advertised rates, and a membership described as available to residents of all 50 states with state-dependent prescribing. Choose TMates if you prioritize 24/7 access to U.S.-based doctors, a flat $199/month semaglutide price that does not increase with dose, and medications formulated in U.S. facilities.
Primary keyword: altRx vs TMates